CN105037553A - 一种能够检测癌症的免疫球蛋白 - Google Patents
一种能够检测癌症的免疫球蛋白 Download PDFInfo
- Publication number
- CN105037553A CN105037553A CN201510513565.4A CN201510513565A CN105037553A CN 105037553 A CN105037553 A CN 105037553A CN 201510513565 A CN201510513565 A CN 201510513565A CN 105037553 A CN105037553 A CN 105037553A
- Authority
- CN
- China
- Prior art keywords
- seqidno
- cdr3
- mmp9
- vlcdr1
- vhcdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 10
- 108060003951 Immunoglobulin Proteins 0.000 title claims description 12
- 102000018358 immunoglobulin Human genes 0.000 title claims description 12
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims abstract description 15
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims abstract description 14
- 230000009870 specific binding Effects 0.000 claims abstract 2
- 201000011510 cancer Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 5
- 238000001514 detection method Methods 0.000 abstract description 2
- 102000054439 human MMP9 Human genes 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 24
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 13
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 13
- 230000009466 transformation Effects 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 4
- 102000013382 Gelatinases Human genes 0.000 description 3
- 108010026132 Gelatinases Proteins 0.000 description 3
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 3
- 108091007196 stromelysin Proteins 0.000 description 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 2
- 102100030417 Matrilysin Human genes 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102100034629 Hemopexin Human genes 0.000 description 1
- 108010026027 Hemopexin Proteins 0.000 description 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 description 1
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 description 1
- 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- 101000577874 Homo sapiens Stromelysin-2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 102000004159 Matrix metalloproteinase-20 Human genes 0.000 description 1
- 108090000609 Matrix metalloproteinase-20 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101100457428 Mus musculus Mmp2 gene Proteins 0.000 description 1
- 101100130654 Mus musculus Mmp9 gene Proteins 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101100130656 Rattus norvegicus Mmp9 gene Proteins 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
人MMP1 | 人MMP2 | 小鼠MMP2 | 人类MMP3 | 人类MMP7 | 人类MMP8 | 人类MMP9 | 猕猴MMP9 | 小鼠MMP9 | 大鼠MMP9 | 人类MMP10 | 人类MMP12 | 人类MMP13 | |
MMP9-1 | >100nM | >100nM | >100nM | >100nM | >100nM | >100nM | 0.14nM | 0.16nM | >100nM | 0.35nM | >100nM | >100nM | >100nM |
MMP9-2 | >100nM | >100nM | >100nM | >100nM | >100nM | >100nM | 0.03nM | >40nM | >100nM | >60nM | >100nM | >100nM | >100nM |
MMP9-3 | >100nM | >100nM | >100nM | >100nM | >100nM | >100nM | 0.02nM | >40nM | >100nM | >60nM | >100nM | >100nM | >100nM |
MMP9-4 | >100nM | >100nM | >100nM | >100nM | >100nM | >100nM | 0.03nM | >40nM | >100nM | >60nM | >100nM | >100nM | >100nM |
MMP9-5 | >100nM | >100nM | >100nM | >100nM | >100nM | >100nM | 0.04nM | >40nM | >100nM | >60nM | >100nM | >100nM | >100nM |
MMP9-6 | >100nM | >100nM | >100nM | >100nM | >100nM | >100nM | 0.03nM | >40nM | >100nM | >60nM | >100nM | >100nM | >100nM |
MMP9-7 | >100nM | >100nM | >100nM | >100nM | >100nM | >100nM | 0.02nM | >40nM | >100nM | >60nM | >100nM | >100nM | >100nM |
MMP9-8 | >100nM | >100nM | >100nM | >100nM | >100nM | >100nM | 0.03nM | >40nM | >100nM | >60nM | >100nM | >100nM | >100nM |
MMP9-9 | >100nM | >100nM | >100nM | >100nM | >100nM | >100nM | 0.02nM | >40nM | >100nM | >60nM | >100nM | >100nM | >100nM |
MMP9-10 | >100nM | >100nM | >100nM | >100nM | >100nM | >100nM | 0.03nM | >40nM | >100nM | >60nM | >100nM | >100nM | >100nM |
MMP9-11 | >100nM | >100nM | >100nM | >100nM | >100nM | >100nM | 0.04nM | >40nM | >100nM | >60nM | >100nM | >100nM | >100nM |
MMP9-12 | >100nM | >100nM | >100nM | >100nM | >100nM | >100nM | 0.02nM | >40nM | >100nM | >60nM | >100nM | >100nM | >100nM |
MMP9-13 | >100nM | >100nM | >100nM | >100nM | >100nM | >100nM | 0.03nM | >40nM | >100nM | >60nM | >100nM | >100nM | >100nM |
MMP9-14 | >100nM | >100nM | >100nM | >100nM | >100nM | >100nM | 0.03nM | >40nM | >100nM | >60nM | >100nM | >100nM | >100nM |
MMP9-15 | >100nM | >100nM | >100nM | >100nM | >100nM | >100nM | 0.02nM | >40nM | >100nM | >60nM | >100nM | >100nM | >100nM |
MMP9-16 | >100nM | >100nM | >100nM | >100nM | >100nM | >100nM | 0.04nM | >40nM | >100nM | >60nM | >100nM | >100nM | >100nM |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510513565.4A CN105037553B (zh) | 2015-08-20 | 2015-08-20 | 一种能够检测癌症的免疫球蛋白 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510513565.4A CN105037553B (zh) | 2015-08-20 | 2015-08-20 | 一种能够检测癌症的免疫球蛋白 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105037553A true CN105037553A (zh) | 2015-11-11 |
CN105037553B CN105037553B (zh) | 2018-04-17 |
Family
ID=54444557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510513565.4A Active CN105037553B (zh) | 2015-08-20 | 2015-08-20 | 一种能够检测癌症的免疫球蛋白 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105037553B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108277214A (zh) * | 2018-02-23 | 2018-07-13 | 广东医科大学 | 一种应激磷酸化抗原多肽、抗体、制备方法以及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103140240A (zh) * | 2010-08-27 | 2013-06-05 | 吉联亚生物科技有限公司 | 基质金属蛋白酶9的抗体 |
WO2013130078A1 (en) * | 2012-02-29 | 2013-09-06 | Gilead Biologics, Inc. | Antibodies to matrix metalloproteinase 9 |
WO2013188846A1 (en) * | 2012-06-15 | 2013-12-19 | Harry Stylli | Methods of detecting diseases or conditions |
-
2015
- 2015-08-20 CN CN201510513565.4A patent/CN105037553B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103140240A (zh) * | 2010-08-27 | 2013-06-05 | 吉联亚生物科技有限公司 | 基质金属蛋白酶9的抗体 |
CN104530238A (zh) * | 2010-08-27 | 2015-04-22 | 吉联亚生物科技有限公司 | 基质金属蛋白酶9的抗体 |
WO2013130078A1 (en) * | 2012-02-29 | 2013-09-06 | Gilead Biologics, Inc. | Antibodies to matrix metalloproteinase 9 |
WO2013188846A1 (en) * | 2012-06-15 | 2013-12-19 | Harry Stylli | Methods of detecting diseases or conditions |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108277214A (zh) * | 2018-02-23 | 2018-07-13 | 广东医科大学 | 一种应激磷酸化抗原多肽、抗体、制备方法以及应用 |
CN108277214B (zh) * | 2018-02-23 | 2021-07-06 | 广东医科大学 | 一种应激磷酸化抗原多肽、抗体、制备方法以及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105037553B (zh) | 2018-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
de Marco | Biotechnological applications of recombinant single-domain antibody fragments | |
CN108779179B (zh) | Cd47抗体、其抗原结合片段及其医药用途 | |
US20200308309A1 (en) | Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies | |
US20220403008A1 (en) | Compositions and methods for the treatment of immunodeficiency | |
JP2021105034A (ja) | 結核菌(Mycobacterium Tuberculosis)感染の診断および治療のための新規な抗−LAMおよび抗−PIM6/LAMモノクローナル抗体 | |
JP6437913B2 (ja) | 複合体特異的抗体及び抗体断片並びにその使用 | |
EP3172233B1 (en) | Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies | |
TWI733695B (zh) | 治療發炎性疾病之方法 | |
Phillips et al. | Rate of asparagine deamidation in a monoclonal antibody correlating with hydrogen exchange rate at adjacent downstream residues | |
CN109071637B (zh) | 结合严重发热伴血小板减少综合征病毒的包膜糖蛋白的抗体及其用途 | |
US20230331824A1 (en) | Single-domain antibodies that bind sars-cov-2 | |
CN103958544B (zh) | 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体 | |
US20160178644A1 (en) | Methods for diagnosing and treating inflammatory bowel disease | |
JP2013518903A5 (zh) | ||
JP2011509245A5 (zh) | ||
RU2668802C2 (ru) | Антитела, используемые для пассивной вакцинации против гриппа | |
WO2015131836A1 (zh) | 一种h7型甲型流感病毒的中和抗体及其用途 | |
JP2014527065A (ja) | インフルエンザウイルス抗体組成物 | |
CN109206516A (zh) | 抗IL-23p19抗体 | |
JP2017537082A5 (zh) | ||
JP2017507131A5 (zh) | ||
CN111902428A (zh) | 一种双特异性抗体及其用途 | |
WO2020073917A1 (en) | Anti-bcma antibodies | |
EP3848390A1 (en) | Methods of treating diseases | |
JP2012523221A5 (zh) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Tian Chunyan Inventor after: Li Jing Inventor before: Li Jing |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180328 Address after: C24-114 Island District waters 028000 economic and Technological Development Zone Tongliao city the Inner Mongolia Autonomous Region Applicant after: Inner Mongolia Meng Yuan Biological Gene Technology Co., Ltd. Address before: 457000 Puyang City Changqing Road and Subei Road intersection drilling two company training and assessment station in Henan Applicant before: Li Jing |
|
TA01 | Transfer of patent application right |